Published in Eur J Pharmacol on March 30, 2000
Safety and Efficacy of Galantamine in Patients With Dementia With Lewy Bodies | NCT00230997
Nicotinic agonists, antagonists, and modulators from natural sources. Cell Mol Neurobiol (2005) 1.53
Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr Bull (2007) 1.21
Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc Natl Acad Sci U S A (2002) 1.17
The positive allosteric modulator morantel binds at noncanonical subunit interfaces of neuronal nicotinic acetylcholine receptors. J Neurosci (2009) 1.13
Galantamine-induced amyloid-{beta} clearance mediated via stimulation of microglial nicotinic acetylcholine receptors. J Biol Chem (2010) 1.04
Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking. Cell Mol Neurobiol (2007) 0.99
Acetylcholine nicotinic receptors: finding the putative binding site of allosteric modulators using the "blind docking" approach. J Mol Model (2005) 0.98
Vascular cognitive impairment: disease mechanisms and therapeutic implications. Neurotherapeutics (2011) 0.97
Current pharmacologic options for patients with Alzheimer's disease. Ann Gen Hosp Psychiatry (2003) 0.94
Physostigmine and galanthamine bind in the presence of agonist at the canonical and noncanonical subunit interfaces of a nicotinic acetylcholine receptor. J Neurosci (2013) 0.93
Effects of neuronal nicotinic acetylcholine receptor allosteric modulators in animal behavior studies. Biochem Pharmacol (2013) 0.93
Morantel allosterically enhances channel gating of neuronal nicotinic acetylcholine alpha 3 beta 2 receptors. Mol Pharmacol (2008) 0.92
Two distinct allosteric binding sites at α4β2 nicotinic acetylcholine receptors revealed by NS206 and NS9283 give unique insights to binding activity-associated linkage at Cys-loop receptors. J Biol Chem (2013) 0.90
Positive allosteric modulator of α7 nicotinic-acetylcholine receptors, PNU-120596 augments the effects of donepezil on learning and memory in aged rodents and non-human primates. Neuropharmacology (2012) 0.90
Modulation of neuronal nicotinic receptor function by the neuropeptides CGRP and substance P on autonomic nerve cells. Br J Pharmacol (2003) 0.89
High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia. Schizophr Res (2008) 0.89
Galantamine, an acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic acetylcholine receptors, attenuates nicotine taking and seeking in rats. Neuropsychopharmacology (2012) 0.88
Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology (Berl) (2005) 0.88
The effects of galantamine on nicotine withdrawal-induced deficits in contextual fear conditioning in C57BL/6 mice. Behav Brain Res (2011) 0.85
Cholinergic modulation by opioid receptor ligands: potential application to Alzheimer's disease. Mini Rev Med Chem (2013) 0.83
Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy. J Psychiatry Neurosci (2006) 0.82
Specificity determinants of allosteric modulation in the neuronal nicotinic acetylcholine receptor: a fine line between inhibition and potentiation. Mol Pharmacol (2011) 0.81
Donepezil, an acetylcholinesterase inhibitor, attenuates nicotine self-administration and reinstatement of nicotine seeking in rats. Addict Biol (2012) 0.80
Functional Chimeras of GLIC Obtained by Adding the Intracellular Domain of Anion- and Cation-Conducting Cys-Loop Receptors. Biochemistry (2015) 0.80
The relationship between associative learning, transfer generalization, and homocysteine levels in mild cognitive impairment. PLoS One (2012) 0.79
Discriminative-stimulus effects of NS9283, a nicotinic α4β2* positive allosteric modulator, in nicotine-discriminating rats. Psychopharmacology (Berl) (2013) 0.79
Repeated administration of an acetylcholinesterase inhibitor attenuates nicotine taking in rats and smoking behavior in human smokers. Transl Psychiatry (2016) 0.79
Intra-subunit flexibility underlies activation and allosteric modulation of neuronal nicotinic acetylcholine receptors. Neuropharmacology (2013) 0.78
Galantamine potentiates the neuroprotective effect of memantine against NMDA-induced excitotoxicity. Brain Behav (2013) 0.78
Subunit interfaces contribute differently to activation and allosteric modulation of neuronal nicotinic acetylcholine receptors. Neuropharmacology (2014) 0.78
MK801- and scopolamine-induced amnesias are reversed by an Amazonian herbal locally used as a "brain tonic". Psychopharmacology (Berl) (2008) 0.77
R-(+) and S-(-) isomers of cotinine augment cholinergic responses in vitro and in vivo. J Pharmacol Exp Ther (2014) 0.77
Pretreatment of Guinea pigs with galantamine prevents immediate and delayed effects of soman on inhibitory synaptic transmission in the hippocampus. J Pharmacol Exp Ther (2010) 0.77
The E loop of the transmitter-binding site is a key determinant of the modulatory effects of physostigmine on neuronal nicotinic α4β2 receptors. Mol Pharmacol (2016) 0.75
Fast and slow mammalian muscles after denervation. Exp Neurol (1970) 2.83
International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol Rev (1999) 2.76
The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci (2001) 2.61
A comparative study of membrane properties of innervated and chronically denervated fast and slow skeletal muscles of the rat. Acta Physiol Scand (1968) 2.42
Choline is a selective agonist of alpha7 nicotinic acetylcholine receptors in the rat brain neurons. Eur J Neurosci (1997) 2.18
Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons. I. Pharmacological and functional evidence for distinct structural subtypes. J Pharmacol Exp Ther (1993) 2.13
Batrachotoxin: chemistry and pharmacology. Science (1971) 2.09
Human bronchial epithelial and endothelial cells express alpha7 nicotinic acetylcholine receptors. Mol Pharmacol (2001) 1.89
Acetylcholine receptor and ion conductance modulator sites at the murine neuromuscular junction: evidence from specific toxin reactions. Proc Natl Acad Sci U S A (1973) 1.82
Choline and selective antagonists identify two subtypes of nicotinic acetylcholine receptors that modulate GABA release from CA1 interneurons in rat hippocampal slices. J Neurosci (1999) 1.80
Neuronal nicotinic acetylcholine receptor activation modulates gamma-aminobutyric acid release from CA1 neurons of rat hippocampal slices. J Pharmacol Exp Ther (1997) 1.67
Nicotinic acetylcholine receptor alpha7 and alpha4beta2 subtypes differentially control GABAergic input to CA1 neurons in rat hippocampus. J Neurophysiol (2001) 1.57
Human and rodent bronchial epithelial cells express functional nicotinic acetylcholine receptors. Mol Pharmacol (1998) 1.56
Perhydrohistrionicotoxin: a potential ligand for the ion conductance modulator of the acetylcholine receptor. Proc Natl Acad Sci U S A (1977) 1.55
alpha-bungarotoxin- and methyllycaconitine-sensitive nicotinic receptors mediate fast synaptic transmission in interneurons of rat hippocampal slices. Brain Res (1998) 1.55
Reaction of tetraethylammonium with the open and closed conformations of the acetylcholine receptor ionic channel complex. J Gen Physiol (1979) 1.54
alpha-Bungarotoxin-sensitive hippocampal nicotinic receptor channel has a high calcium permeability. Biophys J (1995) 1.53
Effect of histrionicotoxin on the ionic conductance modulator of the cholinergic receptor: a quantitative analysis of the end-plate current. J Pharmacol Exp Ther (1974) 1.51
Blockade of nicotinic currents in hippocampal neurons defines methyllycaconitine as a potent and specific receptor antagonist. Mol Pharmacol (1992) 1.50
Levels of batrachotoxin and lack of sensitivity to its action in poison-dart frogs (Phyllobates). Science (1980) 1.46
Kinetic analysis of end plate currents altered by atropine and scopolamine. Mol Pharmacol (1978) 1.45
Human vascular endothelial cells express functional nicotinic acetylcholine receptors. J Pharmacol Exp Ther (1998) 1.45
Nicotinic receptor activation in human cerebral cortical interneurons: a mechanism for inhibition and disinhibition of neuronal networks. J Neurosci (2000) 1.45
A study of the reinnervation of fast and slow mammalian muscles. J Gen Physiol (1973) 1.44
A study of the irreversible cholinesterase inhibitor, diisopropylfluorophosphate, on time course of end-plate currents in frog sartorius muscle. J Pharmacol Exp Ther (1974) 1.43
Effects of batrachotoxin on membrane potential and conductance of squid giant axons. J Gen Physiol (1971) 1.41
Effects of vinblastine and colchicine on neural regulation of the fast and slow skeletal muscles of the rat. Exp Neurol (1972) 1.40
Choline and acetylcholine have similar kinetic properties of activation and desensitization on the alpha7 nicotinic receptors in rat hippocampal neurons. Brain Res (2000) 1.37
A nicotinic acetylcholine receptor regulating cell adhesion and motility is expressed in human keratinocytes. J Invest Dermatol (1995) 1.35
Activation, inactivation, and desensitization of acetylcholine receptor channel complex detected by binding of perhydrohistrionicotoxin. Proc Natl Acad Sci U S A (1980) 1.28
Early membrane depolarization of the fast mammalian muscle after denervation. Pflugers Arch (1971) 1.28
Studies on the nature of the cholinergic receptor. Eur J Pharmacol (1968) 1.27
An electrophysiological and morphological study of the neuromuscular junction in patients with myasthenia gravis. Exp Neurol (1976) 1.26
Binding of perhydro-histrionicotoxin to the postsynaptic membrane of skeletal muscle in relation to its blockage of acetylcholine-induced depolarization. Mol Pharmacol (1977) 1.24
The pharmacology of batrachotoxin. II. Effect on electrical properties of the mammalian nerve and skeletal muscle membranes. J Pharmacol Exp Ther (1971) 1.23
A possible involvement of cyclic AMP in the expression of desensitization of the nicotinic acetylcholine receptor. A study with forskolin and its analogs. FEBS Lett (1986) 1.23
The density of acetylcholine receptors and their sensitivity in the postsynaptic membrane of muscle endplates. Proc Natl Acad Sci U S A (1974) 1.19
Differential effects of perhydrohistrionicotoxin on neurally and iontophoretically evoked endplate currents. Proc Natl Acad Sci U S A (1978) 1.17
Diisopropylfluorophosphate: suppression of ionic conductance of the cholinergic receptor. Science (1973) 1.17
Effects of histrionicotoxin on the chemosensitive and electrical properties of skeletal muscle. Exp Neurol (1975) 1.15
An electrophysiological study of the effects of D-tubocurarine, atropine, and alpha-bungarotoxin on the cholinergic receptor in innervated and chronically denervated mammalian skeletal muscles. Exp Neurol (1974) 1.14
Nicotine at concentrations found in cigarette smokers activates and desensitizes nicotinic acetylcholine receptors in CA1 interneurons of rat hippocampus. Neuropharmacology (2000) 1.14
An analysis of the action of atropine and scopolamine on the end-plate current of frog sartorius muscle. J Pharmacol Exp Ther (1976) 1.12
Influence of phospholipase C on some electrical properties of the skeletal muscle membrane. J Physiol (1967) 1.11
Phencyclidine interactions with the ionic channel of the acetylcholine receptor and electrogenic membrane. Proc Natl Acad Sci U S A (1980) 1.11
Voltage- and time-dependent action of histrionicotoxin on the endplate current of the frog muscle. J Gen Physiol (1978) 1.11
Characterization of batrachotoxin-induced depolarization of the squid giant axons. J Pharmacol Exp Ther (1973) 1.11
Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol Psychiatry (2001) 1.10
Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Mol Pharmacol (1996) 1.10
Sites of action of phencyclidine. II. Interaction with the ionic channel of the nicotinic receptor. Mol Pharmacol (1980) 1.09
Mechanism of action of amantadine on neuromuscular transmission. Mol Pharmacol (1978) 1.08
Morphological and electrophysiological study of distal motor nerve fiber degeneration and sprouting after irreversible cholinesterase inhibition. Synapse (1991) 1.08
Selective blockade of NMDA-activated channel currents may be implicated in learning deficits caused by lead. FEBS Lett (1990) 1.07
The behavioral effects of phencyclidines may be due to their blockade of potassium channels. Proc Natl Acad Sci U S A (1981) 1.06
Effects of normal and myasthenic serum factors on innervated and chronically denervated mammalian muscles. Ann N Y Acad Sci (1976) 1.04
Strychnine: a potent competitive antagonist of alpha-bungarotoxin-sensitive nicotinic acetylcholine receptors in rat hippocampal neurons. J Pharmacol Exp Ther (1998) 1.03
Effects of batrachotoxin on nerve membrane potential and conductances. Nat New Biol (1971) 1.03
The anticonvulsant MK-801 interacts with peripheral and central nicotinic acetylcholine receptor ion channels. J Pharmacol Exp Ther (1990) 1.03
Amantadine: neuromuscular blockade by suppression of ionic conductance of the acetylcholine receptor. Science (1978) 1.02
The effect of calcium on the skeletal muscle membrane after treatment with phospholipase C. Acta Physiol Scand (1968) 1.02
Ethanol potentiates and blocks NMDA-activated single-channel currents in rat hippocampal pyramidal cells. FEBS Lett (1989) 1.01
Meproadifen reaction with the ionic channel of the acetylcholine receptor: potentiation of agonist-induced desensitization at the frog neuromuscular junction. Mol Pharmacol (1982) 1.01
The acetylcholine receptor of the neuromuscular junction recognizes mecamylamine as a noncompetitive antagonist. Mol Pharmacol (1985) 1.01
Electrophysiological observations in normal and dystrophic chicken muscles. Science (1971) 1.00
The acetylcholine receptor and the ionic conductance modulation system of skeletal muscle. Exp Neurol (1975) 1.00
The mechanism and site of action of ketamine on skeletal muscle. J Pharmacol Exp Ther (1981) 0.99
The pharmacology of batrachotoxin. 3. Effect on the heart Purkinje fibers. J Pharmacol Exp Ther (1971) 0.99
The pharmacology of batrachotoxin. IV. Interaction with tetrodotoxin on innervated and chronically denervated rat skeletal muscle. J Pharmacol Exp Ther (1972) 0.99
The pharmacology of batrachotoxin. I. Effects on the contractile mechanism and on neuromuscular transmission of mammalian skeletal muscle. J Pharmacol Exp Ther (1971) 0.99
Photoaffinity labeling of Torpedo acetylcholine receptor by physostigmine. Eur J Biochem (1993) 0.99
Mode of action of quinacrine on the acetylcholine receptor ionic channel complex. Mol Pharmacol (1979) 0.96
Acetylcholine receptor and ionic channel of Torpedo electroplax: binding of perhydrohistrionicotoxin to membrane and solubilized preparations. Biochemistry (1978) 0.96
Electrophysiological and biochemical studies on enhancement of desensitization by phenothiazine neuroleptics. Proc Natl Acad Sci U S A (1983) 0.96
The reversible cholinesterase inhibitor physostigmine has channel-blocking and agonist effects on the acetylcholine receptor-ion channel complex. Mol Pharmacol (1985) 0.95
The effects of batrachotoxin on cat papillary muscle. J Pharmacol Exp Ther (1976) 0.95
alpha7 nicotinic acetylcholine receptors and modulation of gabaergic synaptic transmission in the hippocampus. Eur J Pharmacol (2000) 0.95
Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons. II. The rundown and inward rectification of agonist-elicited whole-cell currents and identification of receptor subunits by in situ hybridization. J Pharmacol Exp Ther (1994) 0.94
Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons. III. Agonist actions of the novel alkaloid epibatidine and analysis of type II current. J Pharmacol Exp Ther (1995) 0.94
[3H]Phencyclidine: a probe for the ionic channel of the nicotinic receptor. Proc Natl Acad Sci U S A (1980) 0.94
Anatoxin-a: a novel, potent agonist at the nicotinic receptor. Mol Pharmacol (1980) 0.94
Differentiation of the open and closed states of the ionic channels of nicotinic acetylcholine receptors by tricyclic antidepressants. Proc Natl Acad Sci U S A (1981) 0.93
Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease. Behav Brain Res (2000) 0.93
Voltage- and time-dependent actions of piperocaine on the ion channel of the acetylcholine receptor. Mol Pharmacol (1979) 0.93
The mode of action of batrachotoxin. Fed Proc (1972) 0.93
Identification and functional characterization of a new agonist site on nicotinic acetylcholine receptors of cultured hippocampal neurons. J Pharmacol Exp Ther (1993) 0.93
Expression of functional alpha7 nicotinic acetylcholine receptor during mammalian muscle development and denervation. Eur J Neurosci (1999) 0.92
The nature of the interactions of pyridostigmine with the nicotinic acetylcholine receptor-ionic channel complex. II. Patch clamp studies. Mol Pharmacol (1984) 0.92
Initial characterization of the nicotinic acetylcholine receptors in rat hippocampal neurons. J Recept Res (1991) 0.92
The nonoxime bispyridinium compound SAD-128 alters the kinetic properties of the nicotinic acetylcholine receptor ion channel: a possible mechanism for antidotal effects. J Pharmacol Exp Ther (1989) 0.92
Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR. Acta Neurol Scand Suppl (2000) 0.92
The pharmacology of batrachotoxin. VII. Structure-activity relationships and the effects of pH. J Pharmacol Exp Ther (1975) 0.92
Studies of human myasthenia gravis: electrophysiological and ultrastructural evidence compatible with antibody attachment to acetylcholine receptor complex. Proc Natl Acad Sci U S A (1976) 0.91
Neostigmine-induced alterations at the mammalian neuromuscular junction. II. Ultrastructure. J Pharmacol Exp Ther (1978) 0.91
The nature of the interactions of pyridostigmine with the nicotinic acetylcholine receptor-ionic channel complex. I. Agonist, desensitizing, and binding properties. Mol Pharmacol (1984) 0.90
Expression of nicotinic acetylcholine receptor subunits in the cerebral cortex in Alzheimer's disease: histotopographical correlation with amyloid plaques and hyperphosphorylated-tau protein. Eur J Neurosci (1999) 0.90
Mapping the location of functional nicotinic and gamma-aminobutyric acidA receptors on hippocampal neurons. J Pharmacol Exp Ther (1996) 0.90
Sites of action of phencyclidine. I. Effects on the electrical excitability and chemosensitive properties of the neuromuscular junction of skeletal muscle. Mol Pharmacol (1980) 0.90
Diversity of nicotinic acetylcholine receptors in rat brain. V. alpha-Bungarotoxin-sensitive nicotinic receptors in olfactory bulb neurons and presynaptic modulation of glutamate release. J Pharmacol Exp Ther (1996) 0.90
Brief-lifetime, fast-inactivating ion channels account for the alpha-bungarotoxin-sensitive nicotinic response in hippocampal neurons. Neurosci Lett (1993) 0.90
The interaction of anticholinesterase agents with the acetylcholine receptor-ionic channel complex. Fundam Appl Toxicol (1984) 0.90